Literature DB >> 10780724

Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.

R A Breen, M C Lipman, M A Johnson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10780724     DOI： 10.1097/00002030-200003310-00017

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

1.  Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Authors:  Ronald J Ellis; Debralee Rosario; David B Clifford; Justin C McArthur; David Simpson; Terry Alexander; Benjamin B Gelman; Florin Vaida; Ann Collier; Christina M Marra; Beau Ances; J Hampton Atkinson; Robert H Dworkin; Susan Morgello; Igor Grant
Journal:  Arch Neurol       Date:  2010-05

2.  Drug-resistant tuberculosis: what are the treatment options?

Authors:  Amr S Albanna; Dick Menzies
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 3.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

Review 5.  Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy.

Authors:  G L Birbeck; J A French; E Perucca; D M Simpson; H Fraimow; J M George; J F Okulicz; D B Clifford; H Hachad; R H Levy
Journal:  Neurology       Date:  2012-01-04       Impact factor: 9.910

Review 6.  Tuberculosis and HIV co-infection: a practical therapeutic approach.

Authors:  Ronan A M Breen; Leonie Swaden; Jayne Ballinger; Marc C I Lipman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection.

Authors:  R A M Breen; R F Miller; T Gorsuch; C J Smith; A Schwenk; W Holmes; J Ballinger; L Swaden; M A Johnson; I Cropley; M C I Lipman
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

8.  Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.

Authors:  Daniel J Westreich; Ian Sanne; Mhairi Maskew; Babatyi Malope-Kgokong; Francesca Conradie; Pappie Majuba; Michele Jonsson Funk; Jay S Kaufman; Annelies Van Rie; Patrick Macphail
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

9.  Timing of antiretroviral therapy and regimen for HIV-infected patients with tuberculosis: the effect of revised HIV guidelines in Malawi.

Authors:  Hannock Tweya; Anne Ben-Smith; Mike Kalulu; Andreas Jahn; Wingston Ng'ambi; Elizabeth Mkandawire; Layout Gabriel; Sam Phiri
Journal:  BMC Public Health       Date:  2014-02-20       Impact factor: 3.295

10.  Incidence and predictors of first line antiretroviral regimen modification in western Kenya.

Authors:  Seth Inzaule; Juliana Otieno; Joan Kalyango; Lillian Nafisa; Charles Kabugo; Josephine Nalusiba; Daniel Kwaro; Clement Zeh; Charles Karamagi
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.